How do police interactions negatively affect African American adolescents mental health?
resort to surgical interventions. Medical treatment of menorrhagia should aim to relieve symptoms, improve quality of life and to avoid the risk of surgery.
The present study was conducted to evaluate the efficacy and safety of oral ormeloxifene and levonorgesterol IUCD in the management of dysfunctional uterine bleeding.
Our study included patients with menorrhagia in the age group 31-50years attending the outpatient department or admitted as inpatients in the department of obstetrics and gynecology at Sri Siddhartha Medical College and Research Centre, Tumkur.
Patients were divided into 2 groups of ormeloxifene and levonorgesterol IUCD. Patients were followed up for 6 months. Pre and post treatment outcome measures in both groups studied were as follows.
– Pre treatment and post treatment assessment of menstrual blood loss objectively by pictorial blood loss assessment chart.
– Blood hemoglobin levels
– Endometrial thickness ( transvaginal scan).
Among 80 patients included in the study, two groups contained 40 patients each. Out of 40 who were treated with oral ormeloxifene, 30 patients attained amenorrhea, 2 patients underwent hysterectomy, 8 patients symptomatically improved. Out of 40 patients treated with levonorgesterol IUCD , 32 patients attained amenorrhea, 1 patient underwent hysterectomy, 4 patients symptomatically improved and 3 patients lost to follow up.
Amenorrhea in our study was defined as absence of bleeding for 3 consecutive cycles.
Symptomatically improved patients = patients in whom cycles were 45-60 days but there was significant reduction in bleeding, reduction in PBAC score, reduction in endometrial thickness and increase in hemoglobin percentage.
In this study, the patients who are treated with oral ormeloxifene shows there was significant reduction in menstrual blood loss as assessed by fall in PBAC score (Table2). The mean pretreatment menstrual blood loss (PBAC score) was 174.20±56.93 which reduced to 22.87±29.90 at 3 months and 3.74±10.99 at 6 months with treatment. There was significant reduction in menstrual blood loss in patients with ormeloxifene. The results of this study (table-2) suggests that the rise in haemoglobin level at the end of 6 months of treatment was 11.03±1.02 compared to the pretreatment level of 10.22±1.36. The rise in
